Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Depreciation & Amortization (CF) (2020 - 2025)

Mirum Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 6 years, most recently at $6.1 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $6.1 million for Q4 2025, changed 0.3% from a year ago — trailing twelve months through Dec 2025 was $24.2 million (up 2.6% YoY), and the annual figure for FY2025 was $24.2 million, up 2.6%.
  • Depreciation & Amortization (CF) for Q4 2025 was $6.1 million at Mirum Pharmaceuticals, roughly flat from $6.1 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for MIRM hit a ceiling of $6.1 million in Q4 2025 and a floor of $79000.0 in Q2 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $2.0 million (2023), compared with a mean of $3.1 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 1204.76% in 2022 and later increased 0.12% in 2025.
  • Mirum Pharmaceuticals' Depreciation & Amortization (CF) stood at $342000.0 in 2021, then soared by 251.17% to $1.2 million in 2022, then skyrocketed by 357.45% to $5.5 million in 2023, then grew by 10.23% to $6.1 million in 2024, then increased by 0.3% to $6.1 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $6.1 million (Q4 2025), $6.1 million (Q3 2025), and $6.1 million (Q2 2025) per Business Quant data.